Seres Therapeutics (MCRB) Earnings Date, Estimates & Call Transcripts → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free MCRB Stock Alerts $0.75 -0.36 (-32.45%) (As of 05/8/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryLatest Earnings DateMay. 8ConfirmedConsensus EPS (May. 8) -$0.36 Listen to Call Get Seres Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for MCRB and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueMCRB Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.MCRB Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Behind the MarketsThe Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> Seres Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.37)($0.37)($0.37)Q2 20241($0.36)($0.36)($0.36)Q3 20241($0.35)($0.35)($0.35)Q4 20241($0.34)($0.34)($0.34)FY 20244($1.42)($1.42)($1.42)MCRB Earnings Date and InformationSeres Therapeutics last released its quarterly earnings results on May 8th, 2024. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.36. Seres Therapeutics has generated ($0.90) earnings per share over the last year (($0.90) diluted earnings per share). Earnings for Seres Therapeutics are expected to grow in the coming year, from ($1.15) to ($0.84) per share. Seres Therapeutics has confirmed that its next quarterly earnings report will be published on Wednesday, May 8th, 2024. Read More Seres Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/8/2024Confirmed)-($0.36)----- 3/5/2024Q4 2023($0.40)($0.32)+$0.08($0.32)$0.50 million$0.06 million11/2/2023Q3 2023($0.47)($0.37)+$0.10($0.37)$1.75 million$0.31 million8/8/2023Q2 2023$0.55$0.36($0.19)$0.36$125.67 million$126.50 million 5/9/2023Q1 2023($0.57)($0.57)-($0.57)$1.58 million($0.52) million 3/7/2023Q4 2022($0.41)($0.54)($0.13)($0.54)$9.04 million$0.98 million11/2/2022Q3 2022($0.45)($0.49)($0.04)($0.49)$12.29 million$3.44 million Get the Latest News and Ratings for MCRB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/3/2022Q2 2022($0.58)($0.70)($0.12)($0.70)$6.03 million$1.22 million5/4/2022Q1 2022($0.56)($0.61)($0.05)($0.61)$7.11 million$1.49 million 3/1/2022Q4 2021($0.45)($0.55)($0.10)($0.55)$19.48 million$7.22 million 11/10/2021Q3 2021($0.47)$0.72+$1.19$0.72$7.12 million$126.73 million 8/3/2021Q2 2021($0.41)($0.53)($0.12)($0.53)$4.40 million$5.26 million Seres Therapeutics Earnings - Frequently Asked Questions When is Seres Therapeutics's earnings date? Seres Therapeutics has confirmed that its next quarterly earnings data will be published on Wednesday, May 8th, 2024. Learn more on MCRB's earnings history. Did Seres Therapeutics beat their earnings estimates last quarter? In the previous quarter, Seres Therapeutics (NASDAQ:MCRB) reported $0.00 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.36) by $0.36. Learn more on analysts' earnings estimate vs. MCRB's actual earnings. How can I listen to Seres Therapeutics's earnings conference call? The conference call for Seres Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How much revenue does Seres Therapeutics generate each year? Seres Therapeutics (NASDAQ:MCRB) has a recorded annual revenue of $126.33 million. How much profit does Seres Therapeutics generate each year? Seres Therapeutics (NASDAQ:MCRB) has a recorded net income of -$113.72 million. MCRB has generated -$0.90 earnings per share over the last four quarters. What is Seres Therapeutics's EPS forecast for next year? Seres Therapeutics's earnings are expected to grow from ($1.15) per share to ($0.84) per share in the next year. More Earnings Resources from MarketBeat Related Companies: CervoMed Earnings Results Regulus Therapeutics Earnings Results AEON Biopharma Earnings Results Syros Pharmaceuticals Earnings Results ProQR Therapeutics Earnings Results Skye Bioscience Earnings Results Greenwich LifeSciences Earnings Results Gossamer Bio Earnings Results scPharmaceuticals Earnings Results Capricor Therapeutics Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (NASDAQ:MCRB) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityWatch this FREE trading tutorial while it’s still availableInvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
